What is the Return on Assets (ROA) of Passage Bio this year?
The Return on Assets (ROA) of Passage Bio is -0.68 undefined this year.
Passage Bio ROA 2025
Passage Bio ROA
-0.68
Ticker
PASG
ISIN
US7027121000
WKN
A2P0EQ
In 2025, Passage Bio's return on assets (ROA) was -0.68, a 21.27% increase from the -0.56 ROA in the previous year.
Passage Bio Aktienanalyse
What does Passage Bio do?
Passage Bio Inc is a biopharmaceutical company focused on the treatment of rare genetic diseases. The company is headquartered in Pennsylvania, USA and was founded in 2018. The beginnings of Passage Bio Inc can be traced back to the work of the Penn Medicine Gene Therapy Program, which has been focusing on researching gene therapies for rare diseases for many years. In 2018, the company was finally founded to bring the research results to the market and help patients with rare diseases. Passage Bio's business model is to develop and market gene therapies based on AAV (Adeno-associated viruses). These viruses are injected into the body and are used to transport healthy genes into cells to replace defective or diseased genes. This can restore the production of missing or damaged proteins, which can contribute to symptom relief and disease cure. The company specializes in developing gene therapies for rare, monogenic diseases that are often caused by a single genetic defect. Such diseases are often difficult to treat and have no effective therapies. Therefore, gene therapies can be a promising option to help patients with these diseases. Passage Bio currently has four gene therapy candidates in its pipeline, all focusing on rare neurological diseases. The first candidate, PBGM01, aims to treat GM1 gangliosidosis, a genetic disorder that leads to impairment of the nervous system and often severe impairment of intellectual and physical development. The other candidates focus on treating diseases such as Krabbe disease, frontotemporal dementia, and Niemann-Pick disease type A. Passage Bio has also partnered with Catalent to support the manufacturing and packaging of its gene therapy products. The two companies are working together to develop a scalable production platform for gene therapy manufacturing, which will enable Passage Bio to produce and distribute therapies on a large scale. Overall, Passage Bio has the potential to change the lives of many patients with rare diseases. By developing gene therapies based on AAV technology, the company can create a promising therapy option for patients who currently have no other options available. With a dedicated team of researchers and development specialists, the company is working hard to develop new gene therapies that can contribute to the relief and cure of rare and serious diseases. Passage Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Passage Bio's Return on Assets (ROA)
Passage Bio's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Passage Bio's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Passage Bio's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Passage Bio’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Passage Bio stock
What was the ROA of Passage Bio compared to the previous year?
The ROA of Passage Bio has increased by 21.27% compared to the previous year.
What consequences do high ROA have for investors of Passage Bio?
A high ROA is advantageous for investors of Passage Bio, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Passage Bio?
A low ROA can be unfavorable for investors of Passage Bio as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Passage Bio affect the company?
An increase in ROA of Passage Bio can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Passage Bio impact the company?
A reduction in the ROA of Passage Bio can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Passage Bio?
Some factors that can influence the ROA of Passage Bio include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Passage Bio important for investors?
The ROA of Passage Bio is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Passage Bio take to improve ROA?
To improve ROA, Passage Bio can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Passage Bio pay?
Over the past 12 months, Passage Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Passage Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Passage Bio?
The current dividend yield of Passage Bio is .
When does Passage Bio pay dividends?
Passage Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Passage Bio?
Passage Bio paid dividends every year for the past 0 years.
What is the dividend of Passage Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Passage Bio located?
Passage Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Passage Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Passage Bio from 1/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/4/2025.
When did Passage Bio pay the last dividend?
The last dividend was paid out on 1/4/2025.
What was the dividend of Passage Bio in the year 2024?
In the year 2024, Passage Bio distributed 0 USD as dividends.
In which currency does Passage Bio pay out the dividend?
The dividends of Passage Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Passage Bio
Our stock analysis for Passage Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Passage Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
